Patients with chronic kidney disease (CKD) display a strong association with atherosclerotic cardiovascular disease (ASCVD) as compared with the general population.1-3 To date, there are no ASCVD risk prediction models to identify optimal treatments and prevention therapies for this high-risk population of CKD.1 A recent study published by Bundy and colleagues in the Journal of the American Society of Nephrology, developed and validated 10-year ASCVD risk prediction models among CKD patients, which included novel kidney and cardiac biomarkers to improve the prediction performance and clinical outcomes.1